DUBLIN--(BUSINESS WIRE)--The "Acromegaly - Market Insights, Epidemiology and Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.
This report delivers an in-depth understanding of the Acromegaly, historical and forecasted epidemiology as well as the Acromegaly market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
The Acromegaly market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Acromegaly market size from 2017 to 2030. The report also covers current Acromegaly treatment practice, market drivers, market barriers, SWOT analysis, reimbursement and market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Acromegaly Diagnosis
The diagnosis of Acromegaly requires demonstration of dysregulated and enhanced GH secretion as well as elevated IGF1 levels, reflective of peripheral tissue exposure to tonically elevated GH concentrations. In Acromegaly, basal GH secretion is tonically elevated with relatively blunted bursts. Accordingly, a random GH value of fewer than 0.04 g/l effectively excludes the diagnosis of Acromegaly. Importantly, an elevated randomly obtained GH measurement may not necessarily imply excessive integrated GH secretion. Net GH secretion is attenuated after the age of 60 (when 24-h GH secretion is less than 50% of that in younger subjects) and by elevated BMI.
Acromegaly Treatment
Various targets for treatment have been used in the past but the current consensus is to aim for growth hormone level of less than 1 g/l after an oral glucose tolerance test and a normal IGF-1 level for age and sex. There is also a general agreement that a basal growth hormone level below 2.5 g/l is an acceptable target to consider the patient as cured.
The treatment options include surgery, medications and radiotherapy. The medication most commonly used in the treatment of Acromegaly are somatostatin analogs (SSAs), dopamine agonists (DA) and growth hormone antagonists. Dopamine agonists are mainly effective in tumors with positive growth hormone plus prolactin immunostaining. Dopamine agonists such as bromocriptine and cabergoline have been used with limited effect in the treatment of Acromegaly. Somatostatin analogs are administered as a parental formulation that suppresses GH secretion by binding to somatostatin receptors, of which there are five subtypes (SST), on somatotrope adenoma cells. Octreotide (Sandostatin) was the first medical treatment for Acromegaly that was effective in a large proportion of patients. Growth hormone antagonists such as Pegvisomant acts in the periphery by to GH receptors and preventing their dimerization; this blocks GH signal transduction and inhibits GH activity, including IGF-I production.
Acromegaly Epidemiology
The disease epidemiology covered in The report provides historical as well as forecasted epidemiology segmented by Total Prevalent Cases of Acromegaly, Total Diagnosed Prevalent Cases of Acromegaly, Origin Specific Cases of Acromegaly, and Diagnosed Cases of Acromegaly Based on Type of Adenomas scenario of Acromegaly in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2017 to 2030.
Key Findings
- As per the analysis, the prevalent cases in the 7MM were 64,508 in 2017.
- The diagnosed patient pool in the 7MM comprised 49,814 patients in 2017.
- In the case of the United States, the prevalent population was estimated to be 28,671 cases in 2017.
- In the US, the diagnosed cases of Acromegaly based on types of Adenomas were 18,349 of macroadenomas and 4,587 of microadenomas in 2017.
- In the Origin based segmentation of Acromegaly in 2017, 21,790 cases were originated at the Pituitary Tumor and the remaining 1,147 Acromegaly cases were from Non-Pituitary Tumor, in the US
- In the EU5, the highest prevalent cases were reported to be in Germany followed by the United Kingdom and France whereas the lowest prevalence rates were reported in Spain from 2017 through 2030
- Japan was reported to have 10,690 prevalent cases in 2017.
Scope of the Report
- The report covers the descriptive overview of Acromegaly, explaining its etiology, signs and symptoms, pathophysiology, genetic basis, and currently available therapies.
- Comprehensive insight has been provided into the Acromegaly epidemiology and treatment.
- Additionally, an all-inclusive account of both the current and emerging therapies for Acromegaly is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
- A detailed review of the Acromegaly market; historical and forecasted is included in The report, covering the 7MM drug outreach.
- The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Acromegaly market.
Report Highlights
- The robust pipeline with novel MOA and oral ROA, increasing prevalence, effectiveness of drugs as both mono and combination therapy will positively drive the Acromegaly market.
- The companies and academics are working to assess challenges and seek opportunities that could influence Acromegaly R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
- Major players are involved in developing therapies for Acromegaly. Launch of emerging therapies will significantly impact the Acromegaly market.
- Our in-depth analysis of the pipeline assets across different stages of development (phase III and phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
Companies Mentioned
- Novartis Pharmaceuticals
- Ionis Pharmaceuticals
- Chiasma Pharma
- Antisense Therapeutics
- Camurus
- GlyTech
- Strongbridge Biopharma
- Crinetics Pharmaceuticals
- Midatech
- Ipsen
- and many others
For more information about this report visit https://www.researchandmarkets.com/r/bp4hor
